Bluetongue (BT) is an economically important, non-contagious viral disease of domestic and wild ruminants. BT is caused by BT virus (BTV) and it belongs to the genus Orbivirus and family Reoviridae. BTV is transmitted by Culicoides midges and causes clinical disease in sheep, white-tailed deer, pronghorn antelope, bighorn sheep, and subclinical manifestation in cattle, goats and camelids. BT is a World Organization for Animal Health (OIE) listed multispecies disease and causes great socio-economic losses. To date, 28 serotypes of BTV have been reported worldwide and 23 serotypes have been reported from India. Transplacental transmission (TPT) and fetal abnormalities in ruminants had been reported with cell culture adopted live-attenuated vaccine strains of BTV. However, emergence of BTV-8 in Europe during 2006, confirmed TPT of wild-type/field strains of BTV. Diagnosis of BT is more important for control of disease and to ensure BTV-free trade of animals and their products. Reverse transcription polymerase chain reaction, agar gel immunodiffusion assay and competitive enzyme-linked immunosorbent assay are found to be sensitive and OIE recommended tests for diagnosis of BTV for international trade. Control measures include mass vaccination (most effective method), serological and entomological surveillance, forming restriction zones and sentinel programs. Major hindrances with control of BT in India are the presence of multiple BTV serotypes, high density of ruminant and vector populations. A pentavalent inactivated, adjuvanted vaccine is administered currently in India to control BT. Recombinant vaccines with DIVA strategies are urgently needed to combat this disease. This review is the first to summarise the seroprevalence of BTV in India for 40 years, economic impact and pathobiology.

Swine coronaviruses (SCoVs) are one of the most devastating pathogens affecting the livelihoods of farmers and swine industry across the world. These include transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), porcine respiratory coronavirus (PRCV), porcine hemagglutinating encephalomyelitis virus (PHEV), swine acute diarrhea syndrome coronavirus (SADS-CoV), and porcine delta coronavirus (PDCoV). Coronaviruses infect a wide variety of animal species and humans because these are having single stranded-RNA that accounts for high mutation rates and thus could break the species barrier. The gastrointestinal, cardiovascular, and nervous systems are the primary organ systems affected by SCoVs. Infection is very common in piglets compared to adult swine causing high mortality in the former. Bat is implicated to be the origin of all CoVs affecting animals and humans. Since pig is the only domestic animal in which CoVs cause a wide range of diseases; new coronaviruses with high zoonotic potential could likely emerge in the future as observed in the past. The recently emerged severe acute respiratory syndrome coronavirus virus-2 (SARS-CoV-2), causing COVID-19 pandemic in humans, has been implicated to have animal origin, also reported from few animal species, though its zoonotic concerns are still under investigation. This review discusses SCoVs and their epidemiology, virology, evolution, pathology, wildlife reservoirs, interspecies transmission, spill-over events and highlighting their emerging threats to swine population. The role of pigs amid ongoing SARS-CoV-2 pandemic will also be discussed. A thorough investigation should be conducted to rule out zoonotic potential of SCoVs and to design appropriate strategies for their prevention and control.

1506 Background: The COVID-19 pandemic created an imperative to re-examine the role of telehealth in oncology. Herein we report trends and demographic disparities in utilization of telehealth and secure messaging (SM; i.e., email via portal/app), before and during the pandemic, at a large integrated healthcare system. Methods: This population-based retrospective cohort study examines utilization of various patient-provider visit types (office, video, telephone) and SM from 1/1/2019-9/30/2020 at 22 Kaiser Permanente Northern California Hematology and Oncology practices. We explored changes associated with the pandemic (i.e., since 03/2020, when stay home orders were introduced) as well as demographic differences, using Chi-square for categorical and the Mann-Whitney U Test for non-parametric comparisons. Results: During the study period, there were 334,666 visits and 1,161,239 SM sent between patients and providers. Since the pandemic, total monthly average of visits declined only slightly by 4.1%, but monthly average office visits decreased by 80% from 11,001 to 2,170, monthly average video visits increased from 40 to 4,666, and monthly average telephone visits increased by 69% from 5,114 to 8,663. The monthly average SM increased by 26% from 50,788 to 64,315. The trend of increasing telehealth utilization was sustained and stabilized between 07-09/2020. New consultations initially decreased from a mean of 1,995 per month (12.4% of all visits) in 2019, to a minimum of 1,179 (8.6%) by 05/2020, returning to 1,619 (11.7%) by 09/2020. Pandemic era video visits were a significantly higher fraction of all visits (p < 0.01) in: (1) younger patients (Gen Z 48%, Gen Y/Millennials 46%; Gen X 40%; Baby Boomers 34.4%; Pre-Boomers 24.5%); (2) patients with commercial insurance (39%) compared to those with Medicaid (32.7%) or Medicare (28.1%); (3) Primary English speakers (33.7%) compared to those who require an interpreter (24.5%);(4) Asians (35%) and non-Hispanic Whites (33.7%) compared to Blacks (30.1%) and Hispanic Whites (27.5%); (5) married/ domestic partner patients (35%) compared to single/divorced/widowed patients (29.9%); (6) patients with a Charlson comorbidity index ≤3 (36.2%) compared to > 3 (31.3%); and (7) males (34.6%) compared to females (32.3%). Similar statistically significant SM utilization patterns were also seen. Conclusions: In the pandemic era, utilization of telehealth and SM rapidly increased in all demographic categories, shifting the landscape and resource allocation of hematology/oncology practices in a manner that is feasible and sustained. New consultations decreased early in pandemic with return to pre-pandemic levels by 09/2020. Utilization of video visits and SM significantly differ between various demographic populations with disparities seen by age, insurance plan, English proficiency, race/ethnicity, marital status, comorbidities, and gender.

No abstract

Trained immunity is a renewed concept of innate immune memory that facilitates the innate immune system to have the capacity to remember and train cells via metabolic and transcriptional events to enable them to provide nonspecific defense against the subsequent encounters with a range of pathogens and acquire a quicker and more robust immune response, but different from the adaptive immune memory. Reversing the epigenetic changes or targeting the immunological pathways may be considered potential therapeutic approaches to counteract the hyper-responsive or hypo-responsive state of trained immunity. The efficient regulation of immune homeostasis and promotion or inhibition of immune responses is required for a balanced response. Trained immunity-based vaccines can serve as potent immune stimuli and help in the clearance of pathogens in the body through multiple or heterologous effects and confer protection against nonspecific and specific pathogens. This review highlights various features of trained immunity and its applications in developing novel therapeutics and vaccines, along with certain detrimental effects, challenges as well as future perspectives.